Schizophrenia genetics: the search for a hard lead by Sullivan, Patrick F
Schizophrenia Genetics: the Search for a Hard Lead
Patrick F. Sullivan, MD, FRANZCP1,2
1Departments of Genetics, Psychiatry, & Epidemiology, University of North Carolina at Chapel Hill
2Department of Medical Epidemiology & Biostatistics, Karolinska Institutet, Stockholm, Sweden
Abstract
Purpose of review—To describe the rationale for searching for genes for schizophrenia, prior
efforts via candidate gene association and genomewide linkage studies, and to set the stage for the
numerous genomewide association studies that will emerge by the end of 2008.
Recent findings—Genomewide association studies have identified dozens of new and
previously unsuspected candidate genes for many biomedical disorders. At least seven new studies
of approximately 20,000 cases plus controls are expected to be completed by the end of 2008.
Summary—Current results have few implications for clinical practice or research, and it is
possible that this recommendation could be dramatically different in a year.
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Introduction
The major question as of this writing in 10/2007 is whether knowledge about the genetic
basis of schizophrenia will be substantially different in a year. Will there be at last a hard
lead that withstands rigorous scrutiny? There are currently multiple studies scheduled for
completion in 2008 that have the potential dramatically to improve understanding of
schizophrenia. These efforts are genomewide association studies (GWAS, “jē' wŏs”), a
relatively new method to elucidate the genetic basis of complex human diseases, and usually
have very large samples by historical standards. In 2007 alone, GWAS has identified dozens
of very strong and replicated associations for multiple different complex traits of biomedical
importance. This review summarizes: the rationale for searching for genes for schizophrenia,
current knowledge of the genetic component to the etiology of schizophrenia, and outlines
the prospects for a substantial advance in the next year.
The Rationale for Searching for Genes for Schizophrenia
The rationale for searching for genes for schizophrenia comes from genetic epidemiological
studies (family, adoption, and twin studies). Table 1 summarizes this body of work1, 2.
Taken together, these data suggest that schizophrenia is familial and that genetic effects are
the predominant component of its familiality. In context, the heritability3 of schizophrenia is
quite high in comparison to many other biomedical disorders. Schizophrenia is known as a
“complex trait” in that its inheritance is complex and does not conform to a typical mode of
inheritance (e.g., autosomal dominant, sex-linked, or mitochondrial). It is critical to note that
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these results are from quasi-experimental studies and do not constitute rigorous proof of the
involvement of genetic variation in the etiology of schizophrenia. Moreover, these results
reveal nothing about the locations of the relevant genomic regions much less their function
or the mechanism by which schizophrenia might result.
Progress to Date in Locating Genes for Schizophrenia
The two major strategies employed prior to 2007 to localize genetic variation for
schizophrenia were candidate gene association studies and genomewide linkage studies.
The conceptual basis of a candidate gene study is straightforward and entails the comparison
of the genotype frequencies for a particular genetic marker in cases with schizophrenia to
appropriately matched controls. An example is given in Figure 1 which shows how a test for
association is created from genotype data. Candidate gene selection is usually based on
knowledge of etiology and, for schizophrenia, most association studies have focused on the
genes encoding proteins involved in some way with dopamine.
There have been at least 1,240 studies of 649 candidate genes in schizophrenia† with COMT
the most intensively studied (70 reports). Despite the tremendous amount of work that has
gone into these studies, the candidate gene approach has not yielded replicable associations
with schizophrenia that meet a high standard of proof. The performance of the candidate
gene approach in schizophrenia research is not dissimilar to results from other complex traits
of biomedical importance4, 5.
The conceptual basis of genomewide linkage studies is more complex, and is based on the
correlations between genotypes and schizophrenia in families. These studies are based on
families usually containing multiple affected individuals. Genetic markers for genomewide
linkage studies (around 300 in the past but now totaling 10,000 or more) are selected to be
relatively evenly spaced across the genome. These studies are not based on prior
pathophysiological knowledge but rather can discover new knowledge about the locations of
genes that might predispose or protect against the development of schizophrenia.
There have been genomewide linkage studies of 31 samples including 6,769 affected
individuals. The results of these studies can be searched and investigated on the web‡. As
discussed and depicted elsewhere2, these results do not appear to converge – no genomic
region was identified by more than a few studies and an improbably large fraction of the
genome (about half) was implicated by at least one study. Moreover, a meta-analysis of
schizophrenia genomewide linkage studies6 was recently updated – genomic regions that
previously met genomewide significance were considerably less impressive and no longer
exceeded genomewide significance.
Comprehensive evaluation of the accumulated work to date is consistent with the following
impressions. First, despite considerable effort, genetic variation that predisposes or protects
against has not yet been identified with compelling replication. Second, evidence for several
highly plausible candidate genes – e.g., NRG17, 8, DTNBP19, 10, or DISC111 – is suggestive
but inconclusive and is dissimilar to the pattern of highly consistent and compelling
replications found for other complex traits. For example, associations of genetic markers in
FTO with body mass index were precisely replicated in 13 cohorts of over 38,000

















requirements for adequate statistical power have almost always been underestimated in prior
studies.
Genomewide Association Studies (GWAS)
In the past two years, technical advances combined with a fortuitous price war have made it
possible to conduct GWAS using large samples. Genotyping for these studies is similar to
that depicted in Figure 1 but scaled up massively. These studies routinely genotype each
individual for 400,000–900,000 genetic variants, and sample sizes usually exceed 1,000
cases and 1,000 controls. A typical GWAS might contain over a billion genotypes (in
contrast, a large genomewide linkage study in the past might have a million genotypes).
Despite considerable skepticism prior to 2007, GWAS have identified strong evidence for
~70 new and previously unknown candidate genes for a variety of biomedical disorder in
2007. As an example, there were three candidate genes for type 2 diabetes mellitus
identified prior to 2007 and there are now at least 10 with all new genes identified by
GWAS13.
There are at least seven on-going GWAS for schizophrenia with results expected by
mid-2008. One small study has been published (whose main result is not replicating well per
unpublished data)14, one has been submitted15, and the remainder are in various stages of
completion. Taken together, these studies total approximately 10,000 cases and 10,000
controls. The major studies include the International Schizophrenia Consortium coordinated
by Dr. Pamela Sklar at the MIT/Harvard Broad Institute (~7000 samples) and the Molecular
Genetics of Schizophrenia group coordinated by Dr. Pablo Gejman of Northwestern
University (~5,000 samples).
A welcome characteristic that has emerged in 2007 is the near-universal willingness of the
investigators in the primary studies to participate in early data sharing. Nearly all
investigators conducting GWAS of schizophrenia have agreed to participate in the
Psychiatric GWAS Consortium (http://pgc.unc.edu) which will conduct high-quality meta-
analyses of schizophrenia along with ADHD, autism, bipolar disorder, and major depressive
disorder. Results of these meta-analyses will be made widely available to the research
community as soon as possible. The total sample size across all these disorders should
exceed 50,000 individuals with GWAS genotyping by the end of 2008.
Conclusion
It is now clear that GWAS can work in the sense of identifying highly replicable
associations for human biomedical disorders of first-rank public health importance.
Examples to date include T1DM, T2DM, Crohn's disease, cardiovascular disease, prostate
cancer, breast cancer, body mass index, and height. The track record of GWAS in human
genetics to date is exceptional and impressive. The key question currently is will it work for
schizophrenia – will our knowledge of schizophrenia genetics be substantially different in
one year? It is never optimal to conclude a review with uncertainty; however, in this
instance, uncertainty is mitigated by the prospect of a convincing demonstration on the one
year horizon of whether there is or is not common genetic variation relevant to the etiology
of schizophrenia.
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Shows an example of an association study for one genetic marker. The genetic marker is the
“famous” COMT val158met polymorphism located on chromosome 22 at base pair position
18,325,825. A “G” at this position codes for valine and an “A” codes for methionine. At the
top of the Figure, DNA in the immediate vicinity of rs4680 is shown with the actual variant
in larger font size. The DNA sequences on either side are the “keys” that allow the specific
interrogation of rs4680 using PCR as the combination of the left and right sequences are
found exactly once in the human genome. People usually have two copies of chr22, one
from each parent. Each of the copies of chr22 could have either an A or a G at position
18,325,825. Thus, these two “alleles” make up a “genotype”. Case #1 inherited an A and a G
– also know as alleles A and G and genotype A/G. Case #2 inherited a G from each parent
and has two copies of allele G and genotype G/G. The basic test for an association between
case/control status and rs4680 genotype is a 2 × 3 contingency table with the cells
containing genotype counts. There is no significant association between case/control status
and rs4680 genotype in this example.
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Summary of studies of the genetic epidemiology of schizophrenia.
Study Type Conceptual basis Studies Findings
Family
Risk of schizophrenia in 1st degree
relatives of cases with schizophrenia vs.
controls
11
• 10/11 studies show familiality of schizophrenia
• Significant familial aggregation of schizophrenia –odds
ratio: 9.8 (95% CI 6.2–15.5)
Adoption
Risk of schizophrenia in adoption
cluster (offspring of one set of parents
raised from early in life by unrelated
strangers
5
• Effect of post-natal environment negligible
• Adoptees with schizophrenia: increased risk in biological vs.
adoptive parents (OR=5.0, 95% CI 2.4–10.4)
• Parents with schizophrenia: increased risk in biological vs.
control offspring 3.5 (95% CI 1.9–6.4)
Twin Risk of schizophrenia in monozygoticvs. dizygotic twins 12
• Heritability in liability to schizophrenia: 81% (95% CI 73–
90%)
• Environmental effects shared by members of a twin pair:
11% (95% CI 3–19%)
Curr Opin Psychiatry. Author manuscript; available in PMC 2011 September 5.
